{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T01:29:33Z","timestamp":1780104573391,"version":"3.54.0"},"reference-count":72,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T00:00:00Z","timestamp":1663804800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Psoriasis is a chronic systemic inflammatory disease that primarily affects the skin and is associated with multiple comorbidities with a considerable reduction in quality of life of affected patients. One-third of psoriasis cases begin in childhood and are associated with significant medical comorbidities such as obesity, metabolic syndrome, arthritis, and psychiatric disorders. In addition, because of its chronic nature and frequent relapses, psoriasis tends to require long-term treatment. Treatment of pediatric psoriasis usually involves the same methods used for adults. However, most treatments for pediatric psoriasis are used off-label, and research in this regard is still lacking. Targeted therapies involving the use of newly developed biologic drugs are also increasingly being applied to childhood psoriasis. This review summarizes the clinical features of pediatric psoriasis and focuses mainly on the updated concepts of pathogenesis and biological treatments of pediatric psoriasis.<\/jats:p>","DOI":"10.3390\/ijms231911128","type":"journal-article","created":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T05:33:14Z","timestamp":1663824794000},"page":"11128","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Biological Treatments for Pediatric Psoriasis: State of the Art and Future Perspectives"],"prefix":"10.3390","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2274-1742","authenticated-orcid":false,"given":"Federico","family":"Diotallevi","sequence":"first","affiliation":[{"name":"Dermatological Clinic, Department of Clinical and Molecular Sciences, Polytechnic Marche University, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oriana","family":"Simonetti","sequence":"additional","affiliation":[{"name":"Dermatological Clinic, Department of Clinical and Molecular Sciences, Polytechnic Marche University, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0091-4067","authenticated-orcid":false,"given":"Giulio","family":"Rizzetto","sequence":"additional","affiliation":[{"name":"Dermatological Clinic, Department of Clinical and Molecular Sciences, Polytechnic Marche University, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Molinelli","sequence":"additional","affiliation":[{"name":"Dermatological Clinic, Department of Clinical and Molecular Sciences, Polytechnic Marche University, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3153-1026","authenticated-orcid":false,"given":"Giulia","family":"Radi","sequence":"additional","affiliation":[{"name":"Dermatological Clinic, Department of Clinical and Molecular Sciences, Polytechnic Marche University, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Offidani","sequence":"additional","affiliation":[{"name":"Dermatological Clinic, Department of Clinical and Molecular Sciences, Polytechnic Marche University, 60126 Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Campanati, A., Marani, A., Martina, E., Diotallevi, F., Radi, G., and Offidani, A. (2021). Psoriasis as an Immune-Mediated and Inflammatory Systemic Disease: From Pathophysiology to Novel Therapeutic Approaches. Biomedicines, 9.","DOI":"10.3390\/biomedicines9111511"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jdermsci.2008.12.012","article-title":"VEGF, survivin and NOS overexpression in psoriatic skin: Critical role of nitric oxide synthases","volume":"54","author":"Simonetti","year":"2009","journal-title":"J. Dermatol. Sci."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000251595","article-title":"The Natural History of Psoriasis in 5600 Patients","volume":"148","author":"Farber","year":"1974","journal-title":"Dermatology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/pde.13382","article-title":"Pediatric psoriasis: Evolving perspectives","volume":"35","author":"Eichenfield","year":"2018","journal-title":"Pediatr. Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s40272-015-0137-1","article-title":"Psoriasis in Children and Adolescents: Diagnosis, Management and Comorbidities","volume":"17","author":"Bronckers","year":"2015","journal-title":"Pediatr. Drugs"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Marani, A., Rizzetto, G., Radi, G., Molinelli, E., Capodaglio, I., Offidani, A., and Simonetti, O. (2022). Metabolic Comorbidities and Cardiovascular Disease in Pediatric Psoriasis: A Narrative Review. Healthcare, 10.","DOI":"10.3390\/healthcare10071190"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jaad.2019.08.049","article-title":"Joint American Academy of Dermatology\u2013National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients","volume":"82","author":"Menter","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1007\/s13555-022-00758-2","article-title":"Update on the Management of Pediatric Psoriasis: An Italian Consensus","volume":"12","author":"Peris","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2174\/18734316MTA35NzY65","article-title":"Novel Therapeutic Approaches and Targets for Treatment of Psoriasis","volume":"22","author":"Radi","year":"2021","journal-title":"Curr. Pharm. Biotechnol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Diotallevi, F., Paolinelli, M., Radi, G., and Offidani, A. (2022). Latest Combination Therapies in Psoriasis: Narrative Review of The Literature. Dermatol. Ther., e15759.","DOI":"10.1111\/dth.15759"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/1364557032000119616","article-title":"Scoping studies: Towards a methodological framework","volume":"8","author":"Arksey","year":"2005","journal-title":"Int. J. Soc. Res. Methodol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1136\/ard.2004.033217","article-title":"Psoriasis: Epidemiology, clinical features, and quality of life","volume":"64","author":"Langley","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0733-8635(03)00125-6","article-title":"An update on the genetics of psoriasis","volume":"22","author":"Capon","year":"2004","journal-title":"Dermatol. Clin."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"BSR20193266","DOI":"10.1042\/BSR20193266","article-title":"Koebner phenomenon leading to the formation of new psoriatic lesions: Evidences and mechanisms","volume":"39","author":"Ji","year":"2019","journal-title":"Biosci. Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.jaad.2017.05.017","article-title":"Skin-infiltrating, interleukin-22-producing T cells differentiate pediatric psoriasis from adult psoriasis","volume":"77","author":"Cordoro","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/sji.12404","article-title":"Characterization of Th17 and FoxP3+Treg Cells in Paediatric Psoriasis Patients","volume":"83","author":"Zhang","year":"2016","journal-title":"Scand. J. Immunol."},{"key":"ref_18","first-page":"1","article-title":"Comparison of Cytokine Expression in Paediatric and Adult Psoriatic Skin","volume":"100","author":"Kim","year":"2020","journal-title":"Acta Derm. Venereol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Kim, H.O., Kang, S.Y., Kim, J.C., Park, C.W., and Chung, B.Y. (2021). Pediatric Psoriasis: From New Insights into Pathogenesis to Updates on Treatment. Biomedicines, 9.","DOI":"10.3390\/biomedicines9080940"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1080\/09546634.2022.2059051","article-title":"Managing pediatric psoriasis: Update on treatments and challenges\u2014A review","volume":"33","author":"Hebert","year":"2022","journal-title":"J. Dermatol. Treat."},{"key":"ref_21","first-page":"172","article-title":"Update on pediatric psoriasis, part 2: Theurapeutic management","volume":"86","author":"Silverberg","year":"2010","journal-title":"Cutis"},{"key":"ref_22","unstructured":"(2022, August 15). A Study to Evaluate the Efficacy, Safety, and Drug Concentration of Certolizumab Pegol (CZP) in Children and Adolescent Study Participants with Moderate to Severe Chronic Plaque Psoriasis (PSO) (CIMcare), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04123795."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(17)31189-3","article-title":"Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: A randomised, double-blind, phase 3 trial","volume":"390","author":"Papp","year":"2017","journal-title":"Lancet"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1080\/09546634.2021.1914306","article-title":"Biologics recommendations for patients with psoriasis: A critical appraisal of clinical practice guidelines for psoriasis","volume":"33","author":"Xie","year":"2022","journal-title":"J. Dermatol. Treat."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.det.2012.12.005","article-title":"Systemic treatments for severe pediatric psoriasis: A practical approach","volume":"31","author":"Marqueling","year":"2013","journal-title":"Dermatol. Clin."},{"key":"ref_26","first-page":"e13091","article-title":"Adalimumab in severe plaque psoriasis of childhood: A multi-center, retrospective real-life study up to 52 weeks observation","volume":"32","author":"Bianchi","year":"2019","journal-title":"Dermatol. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jaad.2010.02.060","article-title":"Patient-reported outcomes in pediatric patients with psoriasis undergoing etanercept treatment: 12-week results from a phase III randomized controlled trial","volume":"64","author":"Langley","year":"2011","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_28","unstructured":"(2021, April 17). Enbrel\u2014etanercept solution Enbrel\u2014etanercept kit. DailyMed, Available online: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=a002b40c-097d-47a5-957f-7a7b1807af7f."},{"key":"ref_29","unstructured":"Weiss, K.D. (2015). Approval of Etanercept for treatment of polyarticular course juvenile rheumatoid arthritis (JRA), Letter to Sally Gould."},{"key":"ref_30","unstructured":"(2021, April 17). European Medicines Agency (EMA). European Medicines Agency. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/enbrel-epar-product-information_it.pdf."},{"key":"ref_31","first-page":"245","article-title":"Etanercept in infants: Suberythrodermic, recalcitrant psoriasis in a 22 month-old child successfully treated with etanercept","volume":"17","author":"Fabrizi","year":"2007","journal-title":"Eur. J. Dermatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.jaad.2010.04.004","article-title":"Long-term etanercept in pediatric patients with plaque psoriasis","volume":"63","author":"Paller","year":"2010","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1001\/jamadermatol.2017.3029","article-title":"Safety of Systemic Agents for the Treatment of Pediatric Psoriasis","volume":"153","author":"Bronckers","year":"2017","journal-title":"JAMA Dermatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jaad.2015.09.056","article-title":"Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis","volume":"74","author":"Paller","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Im, H., Lee, S.H., Lee, H.T., Lee, J.U., Son, J.Y., Shin, W., and Heo, Y.-S. (2018). Structural Biology of the TNF\u03b1 Antagonists Used in the Treatment of Rheumatoid Arthritis. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19030768"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"E75","DOI":"10.1097\/MIB.0b013e3182802c93","article-title":"Infliximab-associated psoriasis in children with Crohn\u2019s disease may require withdrawal of anti-tumor necrosis factor therapy","volume":"19","author":"Broge","year":"2013","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.0736-8046.2004.21121.x","article-title":"Successful treatment of pediatric psoriasis with infliximab","volume":"21","author":"Menter","year":"2004","journal-title":"Pediatr. Dermatol."},{"key":"ref_38","first-page":"e13","article-title":"Childhood generalized pustular psoriasis: Longtime remission with combined infliximab and methotrexate treatment","volume":"32","author":"Weger","year":"2015","journal-title":"Pediatr. Dermatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2147\/PTT.S87650","article-title":"Psoriasis in children","volume":"6","author":"Pinson","year":"2016","journal-title":"Psoriasis: Targets Ther."},{"key":"ref_40","first-page":"123","article-title":"Review of ustekinumab, an interleukin-12 and interleukin-23 inhibitor used for the treatment of plaque psoriasis","volume":"6","author":"Koutruba","year":"2010","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/bjd.19018","article-title":"Ustekinumab for the treatment of moderate-to-severe plaque psoriasis in paediatric patients (\u22656 to <12 years of age): Efficacy, safety, pharmacokinetic and biomarker results from the open-label CADMUS Jr study","volume":"183","author":"Philipp","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jaad.2015.07.002","article-title":"Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: Results of the randomized phase 3 CADMUS study","volume":"73","author":"Landells","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab forthe continuous treatment of patients with moderate to severepsoriasis: Results from the phase III, doubleblinded, placebo-andactive comparator-controlled VOYAGE 1 trial","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1146\/annurev-med-051914-021944","article-title":"Therapeutic Targeting of IL-17 and IL-23 Cytokines in Immune-Mediated Diseases","volume":"67","author":"Fragoulis","year":"2016","journal-title":"Annu. Rev. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1056\/NEJMoa1501646","article-title":"A Phase 2 trial of guselkumab versus adalimumab forplaque psoriasis","volume":"373","author":"Gordon","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_46","first-page":"42","article-title":"Efficacy and safety of guselkumab in patients with psoriasiswho have an inadequate response to ustekinumab: Results of therandomized, double-blind, phase 3 NAVIGATE trial","volume":"38","author":"Langley","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo-and active comparator-controlled VOYAGE 2 trial","volume":"76","author":"Reich","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/bjd.19509","article-title":"A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial*","volume":"184","author":"Blauvelt","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S0140-6736(19)31773-8","article-title":"Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): Results from a phase 3, randomised controlled trial","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"},{"key":"ref_50","unstructured":"(2022, August 15). A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants (PROTOSTAR), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03451851."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1056\/NEJMoa1607017","article-title":"Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis","volume":"376","author":"Papp","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e13802","DOI":"10.1111\/dth.13802","article-title":"A network meta-analysis for the comparison of efficacy and safety of interleukin (IL)-23 targeted drugs in the treatment of moderate to severe psoriasis","volume":"33","author":"Shi","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_53","unstructured":"(2022, August 15). A Study of Subcutaneous Risankizumab Injection for Pediatric Participants with Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04435600."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S0140-6736(17)31279-5","article-title":"Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): Results from two randomised controlled, phase 3 trials","volume":"390","author":"Reich","year":"2017","journal-title":"Lancet"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/bjd.19147","article-title":"Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS)","volume":"183","author":"Paller","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/jdv.17002","article-title":"Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a Phase 3 double-blind randomized, controlled trial","volume":"35","author":"Bodemer","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_57","unstructured":"(2022, August 15). Efficacy and Safety of Brodalumab in Adolescents from 12 to 17 Years of Age with Moderate-to-Severe Plaque Psoriasis (EMBRACE 1), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04305327."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1007\/s12325-022-02126-0","article-title":"Ixekizumab Citrate-Free Formulation: Results from Two Clinical Trials","volume":"39","author":"Chabra","year":"2022","journal-title":"Adv. Ther."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","article-title":"Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis","volume":"373","author":"Lebwohl","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1046\/j.1525-1470.2001.018003188.x","article-title":"Childhood Psoriasis: A Clinical Review of 1262 Cases","volume":"18","author":"Morris","year":"2001","journal-title":"Pediatr. Dermatol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/pde.12072","article-title":"Clinical Manifestations of Pediatric Psoriasis: Results of a Multicenter Study in the United States","volume":"30","author":"Mercy","year":"2013","journal-title":"Pediatr. Dermatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1159\/000247421","article-title":"Plasma Lipid Changes in Psoriatic Children","volume":"185","author":"Simonetti","year":"1992","journal-title":"Dermatology"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1203\/00006450-199305000-00017","article-title":"Changes of Plasma Lipids and Erythrocyte Membrane Fluidity in Psoriatic Children","volume":"33","author":"Ferretti","year":"1993","journal-title":"Pediatr. Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00403-019-01976-z","article-title":"Plasma oxidation status and antioxidant capacity in psoriatic children","volume":"312","author":"Bacchetti","year":"2020","journal-title":"Arch. Dermatol. Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1001\/jamadermatol.2017.5417","article-title":"Association of Psoriasis with Comorbidity Development in Children With Psoriasis","volume":"154","author":"Tollefson","year":"2018","journal-title":"JAMA Dermatol."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Yan, D., Afifi, L., Jeon, C., Cordoro, K.M., and Liao, W. (2018). A cross-sectional study of the distribution of psoriasis subtypes in different ethno-racial groups. Dermatol. Online J., 24.","DOI":"10.5070\/D3247040909"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1111\/jdv.13803","article-title":"DLQI as a major criterion for introduction of systemic agents in patients with mild psoriasis","volume":"30","author":"Mermin","year":"2016","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1111\/ijd.14436","article-title":"Challenges in the treatment of psoriasis with biologics: Vaccination, history of malignancy, human immunodeficiency virus (HIV) infection, and pediatric psoriasis","volume":"58","author":"Plachouri","year":"2019","journal-title":"Int. J. Dermatol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e428","DOI":"10.1111\/jdv.17256","article-title":"Vaccination against SARS-CoV-2 and psoriasis: The three things every dermatologist should know","volume":"35","author":"Diotallevi","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Simonetti, O., Rizzetto, G., Molinelli, E., Diotallevi, F., Radi, G., Cirioni, O., D\u2019Errico, M., and Offidani, A. (2021). Safety and Efficacy of Vaccines during COVID-19 Pandemic in Patients Treated with Biological Drugs in a Dermatological Setting. Healthcare, 9.","DOI":"10.3390\/healthcare9040401"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e13740","DOI":"10.1111\/dth.13740","article-title":"How can I take care of you? The dermatologist meets patients\u2019 needs during the COVID-19 pandemic","volume":"33","author":"Radi","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1080\/14740338.2020.1740204","article-title":"Safety update of etanercept treatment for moderate to severe plaque psoriasis","volume":"19","author":"Campanati","year":"2020","journal-title":"Expert Opin. Drug Saf."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/19\/11128\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:37:10Z","timestamp":1760143030000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/19\/11128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,22]]},"references-count":72,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["ijms231911128"],"URL":"https:\/\/doi.org\/10.3390\/ijms231911128","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,22]]}}}